#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)July 19, 2022

 

 #### Basel, Switzerland

 

 

Novartis announced the company’s financial results for the second quarter and first half of 2022.

 

 

 [    Media release  (268 KB)   ](https://www.novartis.com/sites/novartis_com/files/q2-2022-media-release-en.pdf) [    Medienmitteilung  (257 KB)   ](https://www.novartis.com/sites/novartis_com/files/q2-2022-media-release-de.pdf) [    Communiqué de presse  (264 KB)   ](https://www.novartis.com/sites/novartis_com/files/q2-2022-media-release-fr.pdf) 

 



 [    Interim financial report  (480 KB)   ](https://www.novartis.com/sites/novartis_com/files/2022-07-interim-financial-report-en.pdf) 

 



---

## Investors

[Read the transcript](/investors/financial-data/quarterly-results/2022-q2-transcript "2022 Q2 results presentation and transcript")



[Download the interactive presentation (PDF 2.9 MB)](/sites/novartis_com/files/q2-2022-investor-presentation.pdf)









 



 [ 

 

###  Novartis Pipeline 

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines.

 

 

 ](https://www.novartis.com/research-development/novartis-pipeline) [ 

 

###  Executive Committee of Novartis (ECN) Biographies 

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies.

 

 

 ](/about/executive-committee) 





 

 [Download the Novartis Pipeline, as of December 31, 2021 (PDF 0.1 MB)](/sites/novartis_com/files/q2-2022-investor-presentation.pdf "Download the Novartis Pipeline, as of December 31, 2021 (PDF 0.1 MB)")